Computed Tomography Coronary Angiography for the Prevention of Myocardial Infarction (The SCOT-HEART 2 Trial)
NCT03920176
Recruiting
It is hypothesised that, in individuals being considered for cardiovascular preventative therapy, computed tomography coronary angiography guided management will reduce the future risk of coronary heart disease death or non-fatal myocardial infarction compared to management guided by the current standard of care, a cardiovascular risk score.
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
06/30/2025
Locations: Western General Hospital, Edinburgh, City Of Edinburgh
Conditions: Cardiovascular Diseases
Register for Updates
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
NCT06612203
Recruiting
The WIN-B is an international, multicenter, single-arm, phase Ib/II study to evaluate the safety and activity of the Debio 0123 and Sacituzumab govitecan combination therapy in patients with pre-treated advanced/metastatic TNBC or HR+/HER2- breast cancer. Phase Ib will explore if the addition of increasing doses of Debio 0123 to Sacituzumab govitecan is safe and active in pre-treated advanced/metastatic TNBC and HR+/HER2- breast cancer patients. The Debio 0123's recomendad phase 2 doses (RP2D) o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Hospital Universitari Dexeus, Barcelona, Not set +5 locations
Conditions: Advanced Breast Cancer
Register for Updates
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT03934372
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/30/2025
Locations: Ghent University Hospital, Ghent, Not set +31 locations
Conditions: Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Leukemia, Lymphoma, Solid Tumors
Register for Updates
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
NCT06392009
Recruiting
Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A and one year in Part B/long-term treatment period. The treatment period in Part B may be extended based on... Read More
Gender:
ALL
Ages:
Between 6 months and 18 years
Trial Updated:
06/30/2025
Locations: Queensland Children Hospital, South Brisbane, Not set +19 locations
Conditions: Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Register for Updates
How Healthy Are Your Oats?
NCT07050680
Recruiting
Oat foods are commonly consumed as healthy breakfast options and their nutritional value is well recognised. Oats are a rich source of fibre, micronutrients and non-nutrient bioactive compounds, but at the same time cereals including oats can be contaminated with mycotoxins. To fully understand the nutritional benefits and potential food safety risks of oat consumption, this study aims to assess the nutritional composition of an oat food and the bioavailability of bioactive oat constituents and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/30/2025
Locations: Rowett Institute, University of Aberdeen, Aberdeen, Not set
Conditions: Mycotoxin Biomonitoring
Register for Updates
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
NCT05656469
Recruiting
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
06/30/2025
Locations: SUNY Upstate Medical University, Department of Psychiatry and Behavioural Sciences, Syracuse, New York +8 locations
Conditions: Mood Disorders, Anxiety Disorders, Psychotic Disorders
Register for Updates
Routine Evaluation of People Living With Cancer
NCT04406662
Recruiting
People with incurable cancer often have complex individual needs, however there are several common themes encountered when considering this group. As cancer progresses there are series of interactions between the tumour and the patient, producing both local and systemic effects. This altered state of illness can have multiple ill effects including weight loss, fatigue, increased symptom burden and reduction in physical function which all contribute to a reduced quality of life. These areas are... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: St Columba's Hospice, Edinburgh, Not set
Conditions: Cachexia; Cancer, Advanced Cancer, Quality of Life
Register for Updates
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
Recruiting
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Mayo Clinic - Phoenix, Phoenix, Arizona +173 locations
Conditions: Metastatic Breast Cancer
Register for Updates
International Wilson's Disease Patient Registry (iWilson Registry)
NCT05239858
Recruiting
Longitudinal, observational, non-interventional, standard of care Registry. Data will be collected from the routinely scheduled WD clinic visits at approximately 6-12 month intervals. At enrolment, in addition to data from the clinic visit, retrospective data will be collected from the diagnostic evaluation and any relevant past medical history and a summary of WD medication history.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/30/2025
Locations: University Hospital Leuven, Leuven, Not set +15 locations
Conditions: Wilson's Disease
Register for Updates
Oesophagectomy and Chest Wall and Respiratory Function
NCT03835273
Recruiting
Open surgery for esophageal cancer commonly involves large incisions in the chest, associated with a high rate of pulmonary complications (30-50%). Minimally invasive approach through keyhole surgery has been shown to reduce pulmonary infections by 20%. Enhanced recovery programmes are evidence-based protocols, developed to achieve early recovery after surgery with early mobilisation and chest physiotherapy and have been shown to reduce pulmonary complication rates as well. The investigators int... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/30/2025
Locations: Charing Cross Hospital, London, Not set
Conditions: Esophageal Cancer, Esophagectomy, Respiratory Function Loss
Register for Updates
TrialNet Pathway to Prevention of T1D
NCT00097292
Recruiting
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: Childrens Hospital of Orange County, Orange, California +21 locations
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
NCT03573089
Recruiting
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2025
Locations: Royal Prince Alfred Hosptial, Camperdown, New South Wales +114 locations
Conditions: Kidney Failure, Chronic, Hyperphosphatemia
Register for Updates